Baxter International Inc. (NYSE:BAX) Shares Purchased by Lindbrook Capital LLC

Lindbrook Capital LLC boosted its position in shares of Baxter International Inc. (NYSE:BAX) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,586 shares of the medical instruments supplier’s stock after buying an additional 372 shares during the quarter. Lindbrook Capital LLC’s holdings in Baxter International were worth $177,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pzena Investment Management LLC acquired a new stake in shares of Baxter International during the 3rd quarter valued at about $215,935,000. Carmignac Gestion increased its position in shares of Baxter International by 467.0% in the third quarter. Carmignac Gestion now owns 4,848,773 shares of the medical instruments supplier’s stock valued at $182,992,000 after buying an additional 3,993,537 shares in the last quarter. Shapiro Capital Management LLC acquired a new position in shares of Baxter International during the 3rd quarter worth approximately $114,307,000. Bank of New York Mellon Corp lifted its position in shares of Baxter International by 69.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 6,491,343 shares of the medical instruments supplier’s stock valued at $244,983,000 after buying an additional 2,650,959 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Baxter International by 11.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 10,836,563 shares of the medical instruments supplier’s stock valued at $408,992,000 after acquiring an additional 1,098,787 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Stock Up 2.4 %

Shares of BAX opened at $40.40 on Tuesday. The stock has a fifty day simple moving average of $41.80 and a two-hundred day simple moving average of $38.46. The company has a quick ratio of 1.04, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $20.52 billion, a PE ratio of 7.74, a price-to-earnings-growth ratio of 2.12 and a beta of 0.62. Baxter International Inc. has a 52-week low of $31.01 and a 52-week high of $50.21.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.02. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.81 billion. Baxter International had a net margin of 17.77% and a return on equity of 19.49%. Baxter International’s revenue was up 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.88 earnings per share. As a group, equities analysts forecast that Baxter International Inc. will post 2.89 EPS for the current year.

Baxter International Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Investors of record on Friday, March 1st were given a $0.29 dividend. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.16 annualized dividend and a yield of 2.87%. Baxter International’s payout ratio is 22.22%.

Analyst Upgrades and Downgrades

BAX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Baxter International from $38.00 to $44.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Citigroup upped their price target on shares of Baxter International from $41.00 to $44.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Bank of America raised their price target on shares of Baxter International from $42.00 to $45.00 and gave the company a “neutral” rating in a research note on Tuesday, March 5th. Barclays boosted their price objective on Baxter International from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Monday, February 12th. Finally, UBS Group reduced their target price on Baxter International from $40.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $46.30.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.